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I n t r o d u c t i o n.  Between the years 1985 and1994 at the Maria Sklodowska-Curie Memorial Cancer Center and Institute of
Oncology in Warsaw two radiotherapy techniques were used in the case of postmastectomy breast cancer patients. In
technique “A”, in order to limit cardiotoxicity, peripheral nodes only were irradiated, in technique “B” the chest wall was
additionally treated. Usually technique “B” was chosen in more advanced cases, but generally the selection of the technique
was left to the discretion of the attending physician.
A i m.  To estimate disease free survival (DFS) and overall survival (OS) with regard to prognostic factors, to evaluate loco-
regional failures as related to the radiotherapy technique and to assess early and late morbidity.
M a t e r i a l  a n d  m e t h o d s.  The retrospective analysis included 507 postmastectomy patients consecutively irradiated
for breast cancer in stage IA – IIIB. Median age was 57 years. Median follow-up was 10 years. The incidence of patients with
pN1 stage was 90% and with pN0 10%. We applied a total dose of 50 Gy in 25 fractions, over 5 weeks, with Co60 to the
supraclavicular area, axillary and internal mammary nodes. The chest wall was irradiated with electrons to a total dose of 46
Gy at 90% izodose in 23 fractions over 5 weeks. Three-dimensional treatment planning of the chest wall was used. Technique
“A” and “B” were used in 62% and 38% of patients, respectively. Simultaneously with radiotherapy 67% of patients received
chemotherapy (CMF), and/or hormonotherapy (tamoxifen). In 33% of patients no systemic treatment was administered. We
analysed the influence of the following prognostic factors: age and hormonal status, additional diseases, duration of symptoms
before treatment, breast laterality, T- stage, breast tumour location, carcinoma type, tumour grade, nodal index, extranodal
extention and vascular invasion on disease free survival (DFS) and overall survival (OS); in a univariate analysis with the
Kaplan-Meier method and in a multivariate analysis with the Cox’s proportional-hazards regression model.
R e s u l t s.  The 5- and 10-year actuarial DFS and OS for the entire group were 48%, 38% and 62%, 42%, respectively.
In univariate analysis: T- stage, breast tumour location, carcinoma type, tumour grade, nodal index, extranodal
extention and vascular invasion were statistically significant associated with DFS and/or OS. In multivariate analysis
the following prognostic factors had statistically detrimental significant effect on the risk of distant and/or local
recurrence of breast cancer: young age (relative risk (RR) 1.36; p<0.015), central or medial tumour location (RR 1.47;
p<0.005), extranodal extention (RR 1.58; p<0.011),nodal index (if more than 60% RR=2.26 p<0.0001). The same
factors (except age) had influence on the risk of death due to breast cancer. During the 5-year of follow-up, in 40% distant
failures (DF) and in 6% of patients, isolated loco-regional recurrence (LRR) was found. Throughout follow-up LRR’s
(isolated or with DF) were recognised in 14% of patients, regardless of the radiotherapy technique. 76% of LRRs
appeared during the first 5 years and 90% – during 6.5 years of follow-up. The chest wall recurrence was the most frequent LRR
for technique “A” and “B”, ocurring in 10% and in 9.3% of pts. respectively. Recurrences in irradiated nodal areas appeared
very rarely – in 0.3% – 1.7% of patients. In T1 – T2 pN1 patients, irradiated with technique “A” chest wall recurrence
occurred in 11% and in patients with nodal index below 40% – in 8.5%. This data indicates the need of chest wall
irradiation in such patients. The tolerance of postmastectomy irradiation was good. Early and late skin reactions were
acceptable, although more evident following electron irradiation. In 5.6% of patients who had concurrently
received chemotherapy we observed short delays in radiotherapy due to leucopoenia. The following forms of postmastectomy
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Introduction
In Poland breast cancer is the most common malignancy
recognised in women (structure index 19.7%, incidence
36). Approximately 11 000 new cases are diagnosed per
annum [1]. It is estimated that radical mastectomy is
performed in some 8000 of these patients, and that some
3500 of those necessitate adjuvant radiotherapy. The
main indications for radiotherapy after mastectomy
include the involvement of more than 3 axillary lymph
nodes and/or the size of the initial tumour exceeding 5 cm
[2, 3]. Some authors suggest adjuvant irradiation in
patients with only 3 involved lymph nodes, stressing that
in these patients the efficacy of irradiation is even higher
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irradiation late morbidity were observed: in 27 (10%) patients lymphoedema of the arm, in 6 (2.2%) lung fibrosis without
symptoms, in one (0.4%) transient brachial plexopathy, in 4 (1.5%) coronary heart disease and in one (0.4) patient –
hypothyreosis.
Wyniki uzupe∏niajàcego leczenia chorych po mastektomii z powodu raka piersi, 
napromienianych w Centrum Onkologii w Warszawie w latach 1985-1994
W p r o w a d z e n i e.  W Centrum Onkologii w Warszawie w latach 1985-1994 stosowano w radioterapii uzupe∏niajàcej
u chorych po radykalnej mastektomii z powodu raka piersi dwie techniki napromieniania. W technice A, w celu ograniczenia
kardiotoksycznoÊci, napromieniano Co 60 tylko regionalne w´z∏y ch∏onne, a w technice B napromieniano dodatkowo Êcia-
n´ klatki piersiowej. Technik´ „B” stosowano u chorych z wi´kszym zaawansowaniem. Jednak˝e, ostateczny wybór techniki
leczenia by∏ arbitralny.
C e l.  Ocena prze˝ycia bezobjawowego i ca∏kowitego, z uwzgl´dnieniem czynników prognostycznych, analiza niepowodzeƒ lo-
ko-regionalnych, z uwzgl´dnieniem techniki radioterapii oraz ocena wczesnych i póênych powik∏aƒ.
M a t e r i a ∏  i m e t o d y.  Retrospektywnà analizà obj´to 507 kobiet chorych na raka piersi, napromienianych po mastektomii,
w stopniu zaawansowania od IA do IIIB. Mediana wieku wynosi∏a 57 lat. Mediana obserwacji – 10 lat. U 90% chorych roz-
poznano pN1, a u 10% pN0. Okolic´ w´z∏ów ch∏onnych nad- i podobojczykowych, pachowych i przymostkowych napromie-
niano Co 60, podajàc ca∏kowità dawk´ 50 Gy w 25 frakcjach w czasie 5 tygodni. Âcian´ klatki piersiowej napromieniano wiàz-
kà elektronów do dawki ca∏kowitej 46 Gy, obliczanej w izodozie 90%, podanej w 23 frakcjach w czasie 5 tygodni. W radio-
terapii Êciany klatki piersiowej wykorzystywano trójwymiarowe planowanie leczenia. Technik´ „A” zastosowano u 62%,
a technik´ „B” u 38% chorych. U 67% chorych radioterapi´ skojarzono z jednoczasowà chemio- (CMF) lub hormonotera-
pià (tamoksyfen). U 33% chorych nie stosowano leczenia systemowego. W analizie jednoczynnikowej i wieloczynnikowej zba-
dano wp∏yw nast´pujàcych czynników prognostycznych na ryzyko nawrotów i zgonu z powodu raka piersi: wiek i stan hormo-
nalny chorych, choroby wspó∏istniejàce, czas wywiadu, strona piersi, wielkoÊç i lokalizacja guza pierwotnego, typ histopato-
logiczny raka, stopieƒ z∏oÊliwoÊci raka, indeks w´z∏owy, stosunek raka do torebki w´z∏a i tkanki otaczajàcej, inwazja naczyƒ.
W obliczeniach wykorzystano metod´ Kaplana-Meiera i modele proporcjonalnego ryzyka Cox’a.
W y n i k i.  Pi´cio- i 10-letnie prze˝ycie bezobjawowe i ca∏kowite dla ca∏ej grupy chorych wynios∏o odpowiednio: 48%, 38%,
62% i 42%. W analizie jednoczynnikowej takie czynniki, jak: wielkoÊç i lokalizacja guza pierwotnego, typ histopatologiczny
raka, stopieƒ z∏oÊliwoÊci raka, indeks w´z∏owy, stosunek raka do torebki w´z∏a i tkanki otaczajàcej, inwazja naczyƒ, okaza-
∏y si´ mieç istotny statystycznie zwiàzek z prze˝yciem bezobjawowym i ca∏kowitym. W analizie wieloczynnikowej czynnikami
istotnie statystycznie zwi´kszajàcymi ryzyko nawrotu okaza∏y si´: m∏ody wiek (ryzyko wzgl´dne 1,36; p<0,015), centralna i przy-
Êrodkowa lokalizacja guza w piersi (ryzyko wzgl´dne 1,47; p<0,0005), naciek torebek w´z∏ów ch∏onnych (ryzyko wzgl´dne 1,58;
p<0,011) i indeks w´z∏owy (jeÊli powy˝ej 60%, to ryzyko wzgl´dne 2,26; p<0,0001). Te same czynniki, oprócz wieku, mia∏y
istotny wp∏yw na ryzyko zgonu z powodu raka piersi. W ciàgu 5 lat obserwacji u 40% chorych wystàpi∏y przerzuty odleg∏e,
a u 6% samodzielne nawroty loko-regionalne. W ca∏ym okresie obserwacji nawrót loko-regionalny (samodzielny lub z prze-
rzutem) rozpoznano u 14% chorych, bez wzgl´du na rodzaj stosowanej techniki radioterapii. Siedemdziesiàt szeÊç procent na-
wrotów pojawi∏o si´ w ciàgu pi´ciu lat, a 90% w ciàgu 6,5 roku. Najcz´Êciej w obu technikach „A” i „B” wznow´ obserwowa-
no w Êcianie klatki piersiowej, odpowiednio: u 10% i 9,3% chorych. Nawroty w napromienianych obszarach w´z∏owych wy-
st´powa∏y sporadycznie, od 0,3% do 1,7% chorych. Wznowy w Êcianie klatki piersiowej u chorych z guzem pierwotnym
T1-2 pN1, leczonych technikà „A”, wystàpi∏y u 11% chorych, a u chorych z indeksem w´z∏owym poni˝ej 40% u 8,5% chorych.
Potwierdza to koniecznoÊç napromieniania tych grup chorych na obszar Êciany klatki piersiowej. Tolerancja napromieniania
by∏a dobra. Wczesne i póêne odczyny skórne by∏y akceptowalne. Nieco bardziej by∏y one nasilone po radioterapii elektrono-
wej. U 5,6% chorych leczonych jednoczasowo z CMF zastosowano przerw´ w napromienianiu z powodu leukopenii. U 27
(10%) chorych stwierdzono obrz´k koƒczyny górnej, u 6 (2,2%) zw∏óknienie popromienne w p∏ucach nie powodujàce obja-
wów klinicznych, u jednej (0,4%) przemijajàce objawy uszkodzenie splotu ramiennego, u 4 (1,5%) nasilenie choroby
wieƒcowej i u jednej (0,4%) niedoczynnoÊç tarczycy.
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[4, 5]. Randomized clinical trials held in the recent years
have shown that irradiation not only reduces the risk of
recurrence, but also improves overall survival in patients
receiving systemic treatment [6-10].
Since the fifties irradiation after mastectomy has
been a routine procedure at the Maria Sklodowska-Curie
Memorial Cancer Centre and Institute of Oncology in
Warsaw. Until the seventies we used roentgenotherapy,
and later – cobaltotherapy. In the beginning of the
eighties we introduced simulators, CT scans and 3D
treatment planning. In 1985 we introduced electron beam
irradiation of the chest wall in order to minimalize the risk
of late complications [11-13].
Irradiation after mastectomy was performed
using two different techniques. The first technique –
intended to minimalize the complication risks – included
only the irradiation of local lymph nodes (the so-called
“peripheral” technique). The second technique consisted
of irradiation of the lymph nodes and of the chest wall
(referred to as the “peripheral + chest wall” technique).
After 10 years of patient observation we performed
a retrospective analysis of the results.
The aims of this paper are:
1) to evaluate disease-free survival (DFS) and overall
survival (OS) including a univariate and multivariate
analysis of prognostic factors,
2) to analyse loco-regional failures and to attempt to
solve the query – is it rational to refrain from
irradiation of the chest wall in selected sub-groups of
patients, e.g. T1-T2 tumours with a low nodal index,
3) to evaluate the tolerance of radiotherapy after
mastectomy and to analyse the early and the late
complications.
Material
The study group consisted of 507 consecutive women with breast
cancer after mastectomy who had been irradiated at the 2nd
Department of Radiotherapy of the Maria Sklodowska-Curie
Memorial Cancer Centre and Institute of Oncology in Warsaw
(referred to as Institute of Oncology) between the years 1985
and 1994. Indications for postoperative radiotherapy included
metastases in axillary lymph nodes found after lymphadenectomy
and/or tumour size over 5 cm. According to the protocol only
post-menopausal women were to be qualified for postoperative
irradiation, however there were some exceptions. These included
women with multiple nodal involvement, and/or with
histopathologically highly malignant tumours (G3). These
patients account for some 12% (62/507) of the entire group.
Patient characteristics are presented in Table I. A vast majority of
patients were over 50 years of age (70%) and postmenopausal
(88%). The youngest patient was 29, the oldest – 78. Median age
was 57 years. Almost half of the patients (45%) had at least one
concomitant disease – diabetes, arterial hypertension or coronary
heart disease. A majority of the patients (91%- 462/507) had
been operated in general surgical wards. Only 9% of the patients
(45/507) had undergone mastectomy at the Institute of Oncology
in Warsaw. 70% (354/507) had undergone mastectomy modo
Patey, 17% (85/507) – mastectomy modo Halstedt and 1%
(4//507) – modo Urban. In 12% of patients (64//507) operated
outside the Institute of Oncology residual breast tissue was
found despite “so-called” radical mastectomy. In over 2/3 of the
patients the mastectomy was performed more than six months
after the first symptoms of breast cancer. 89% of patients
reported with a tumour over 2 cm in size, in 25% of patients the
tumour was over 5 cm in diameter or the skin was infiltrated.
The relatively small number of excised lymph nodes (7 on
average) from the axilla caused difficulties in making therapeutic
decisions. In order to assess the advancement of the disease we
checked surgical protocols and consulted almost all histo-
pathological specimens. In 66% of cases invasive ductal
carcinoma was diagnosed, in 16% – invasive lobular carcinoma
and in 5% of cases – other types of breast cancer with a better
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Table I. Clinical characteristics of 507 patients (pts)
Factor Number of pts. (%)
Age (yrs.) 29–78 (median: 57) 153 (30)
< 50 354 (70)
>= 50
Pre-menopausal 62 (12)
Postmenopausal 445 (88)
Additional no 277 (55)
diseases yes 230 (45)
Anamnesis (mths.) 136 (27)
1–48 mths. = < 6 371 (73)
(median: 4) > 6
Breast laterality: right 245 (48)
left 262 (52)
Breast tumour location:
lateral quadrants 66 (13)
central location 279 (55)
medial quadrants 162 (32)
I° T1pN0 8 (2)
II°A T1pN1 47 (9)
T2pN0 33 (7)
II°B T2pN1 293 (57)
T3pN0 8 (2)
III°A T3pN1 80 (16)
III°B T4pN1 38 (7)
Carcinoma type:
ductal invasive 332 (66)
lobular invasive 81 (16)
good prognostic group 27 (5)
no data 67 (13)
No. of nodes removed:
0–36
(median: 7) 1-6 169 (33)
>6 292 (58)
no data 46 (9)
No. of nodes involved:
0–28
(median: 3) 1-3 218 (43)
4-8 157 (31)
=> 9 86 (17)
no data 46 (9)
Extranodal extention:
no 127 (25)
yes 380 (75)
Tumor Grade:
G I 14 (3)
G II 200 (39)
G III 82 (16)
no data 211 (42)
Vascular invasion:
no 370 (73)
yes 137 (27)
prognosis. In 13% of patients receiving preoperative chemo-
therapy it had been impossible to diagnose the histopathological
type of the tumour. 90% of the entire group (458/507) presented
an axillary lymph node metastases. The remaining 49 patients
(10%) appeared not to have nodal involvement – however the
analysed specimens from these patients contained, on average,
less than 6 lymph nodes, or, in some cases – the number of
lymph nodes was unknown, and therefore they also underwent
postoperative irradiation. Third pathological grade, vascular
invasion and extranodal extension were recognised in 16%, 27%
and 75%, respectively.
Po s t o p e r a t i v e  i r r a d i a t i o n
In all patients postoperative irradiation was started some 2-3
months after mastectomy. Two different techniques of irradiation
were used. In the first technique – referred to as “peripheral”
(A) – the irradiated field included axillary, supra- and
infraclavicular lymph nodes without the chest wall. In the second
technique – the so-called “peripheral and chest wall” technique
we irradiated the lymph nodes and the postmastectomy chest
wall. Patients with lesser advancement and a higher complication
risk were qualified for technique A and patients with further
advancement were qualified for technique B. However, the final
choice of treatment was arbitrary and depended also on the
accessibility to the CT – computed tomography and to the
accelerator. Radiotherapy was planned on the simulator. Supra-
and infraclavicular nodes were irradiated with Co60 with one
frontal field, with a 10 degree lateral rotation in order to avoid
irradiating the pharynx and the oesophagus. We used individual
shields for the larynx and the entire head of the humerus. We
administered a total dose of 50 Gy in 25 fractions calculated
for the 100% isodose. The dose was increased in the centre of
the axillary fossa from an additional backward field, using the
isocentric technique without altering the position of the patient.
This allowed to achieve a total isodose of 50 Gy in 25 fractions
within the centre of the AP distance of the axilla over the same
treatment time. The internal mammary nodes were irradiated
with a mixed beam – a total dose of 30 Gy of Co60 calculated for
the 100% isodose in 15 fractions and a total dose of 18 Gy of
a 12 or 15 MeV electron beam calculated for the 80% isodose in
9 fractions. The chest wall and the internal mammary nodes
were irradiated with an electron beam. We performed 3D
planning with CT sections of the chest wall taken every 2 cm.
The planning treatment volume (PTV) was inserted at each
scan. The Helax planning system allowed to calculate the energy
and the electron beam angles. We used individual wax boluses to
shape the electron beam so that the chest wall (PTV) would be
in the 80% isodose, and to diminish the volumes of critical
organs (heart, lungs). We administered a total dose of 46 Gy
calculated for the 80% isodose in 23 fractions. In 313/507
patients (62%) we irradiated the lymph nodes only (technique
A), while in 194/507 patients (38%) the irradiated area also
included the chest wall (technique B).
S y s t e m i c  t r e a t m e n t
In 167/507 patients (33%) no systemic treatment was administe-
red. In the remaining 340/507 patients (67%) postoperative
irradiation was administered together with chemo- or
hormonotherapy. In 284/445 postmenopausal patients (64%)
tamoxifene was administered for 5 years as adjuvant therapy.
The estrogen and progesterone receptors had not been
evaluated in a vast majority of patients. In 192/507 patients
(38%) postoperative chemotherapy was applied. 88 patients
(17%) received 6 courses of the CMF programme (cyclophos-
phamide 100 mg/m2 orally on days 1-14; methotrexate 40 mg/m2
i.v. on day 1 and 8; 5-fuorouracil 600 mg/m2 i.v. on day 1 and 8)
every 28 days. The remaining 104 patients (21%) received
complex preoperative chemotherapy due to poor prognosis –
12 courses according to the Ansfield programme (cyclophos-
phamide 100 mg/m2 orally day 1-14; prednisone 45-15 mg/day;
methotrexate 30 mg/m2 i.v. and 5-fuorouracil 500 mg/m2 i.v.
every 7 days and vincristine 1 mg i.v. every 7 days). After
mastectomy these patients additionally received 3 courses
according to the CMF programme and tamoxifene.
Observation was terminated in December 2001. The
observation time varied between 7 and 15.5 years (median – 10
years). Late complications were analysed according to the
RTOG-EORTC and NCI Common Toxicity Criteria-CTC.
Statistical methods
The first stage included a univariate analysis with a calculation of
the 5- and 10-year DFS and OS using the Kaplan-Meier method
[14]. We analysed the following prognostic factors: age and
hormonal status, concomitant diseases, duration of case history,
breast laterality, size and location of the primary tumour,
histological grade, nodal index (ratio of involved nodes in all
dissected), extranodal extension and vascular invasion.
In the second stage we performed a multivariate analysis
using Cox’s proportional hazards model [15]. We used stepwise
elimination for the modelling, excluding factors for which the p
value was the highest, but not lower than 0.1. The level of
statistical significance was assumed for α =0.05.
In the next stage we checked the frequency and structure of
the first failures during a 5-year observation period. We also
registered loco-regional failures (isolated and/or with
simultaneous distant failures) throughout the observation period
in relation to the applied irradiation technique. The cumulated
frequency of loco-regional failures was calculated according to
the Kaplan-Meier method [14].
Results
In the entire group of 507 breast cancer patients
irradiated after mastectomy 273 (54%) died. An analysis
of the causes of death had shown that 244 (48%) of
patients had died of breast cancer dissemination. 5
patients (1%) died due to other causes, i.e. stroke, heart
disease, ovarian cancer, colorectal cancer and lung cancer.
In 24 cases (5%) we failed to discover the cause of death.
Among the 234 survivors (46%) 201 patients (40%) are
symptom-free and 33 (6%) have reported with symptoms
of the malignancy. In 21 patients (4%) we have diagnosed
cancer of the second breast.
D F S  a n d  O S  i n  v i e w  o f  u n i v a r i a t e
a n d m u l t i v a r i a t e  a n a l y s i s  o f  t h e
p r o g n o s t i c  f a c t o r s
The probability of 5- and 10-year DFS and OS in the
entire group of patients was 48%, 38% and 62%, 42%,
respectively.
In the course of the univariate analysis we found
that the following prognostic factors had a statistically
significant impact on DFS and OS: size and location of
the primary tumour, histological type, nodal index, the
infiltration of the nodal capsule and surrounding tissue
and vascular invasion – Table II. The histopathological
grade of the tumour did not affect the risk of recurrence,
but it had a statistically significant impact on OS. All
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other analysed factors (age, hormonal status, concomitant
diseases, duration of case history and the breast laterality)
had no influence either on DFS or OS.
In the multivariate analysis the following factors
were found to have a statistically significant influence on
recurrence: age, location of the primary tumour, nodal
index and the infiltration of the nodal capsule and
surrounding tissue – Table III.
Younger patients – up to 45 years of age – had an
almost twice as high risk of recurrence and death as
compared to older patients. Only patients between 55
and 65 years of age formed an exception, as in their case
the risk of recurrence was similar to that found in younger
women. Patients with central or medial tumour location
within the breast had a 1.5 times higher risk of recurrence
than patients with lateral tumour location. The risk of
recurrence was also 1.5 times higher in patients with
extracapsular nodal infiltration. The greatest risk of
recurrence was observed in patients with the highest nodal
index – patients with a nodal index of over 60% had a 2.3
times higher risk of recurrence than patients with the
nodal index below 40% – Table III.
In the course of an analysis of the factors influencing
the death risk we found that in this case practically the
same factors are significant, except for age. Patient with
central or medial tumour location have a 60% higher
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Table II. 5 and 10 – year disease free survival (DFS) and overall survival (OS) 
in 507 postmastectomy breast cancer patients as related to prognostic factors
Prognostic factors Number of pts. 5 year DFS%()* 10 year DFS%()* 5 year OS%()* 10 year OS%()*
Total group 507 48 (44;52) 38 (34;42) 62 (58;66) 42 (38;46)
Age:
29-45 88 36 (26;46) 25 (17;33) 57 (47;67) 33 (23;43)
46-55 133 52 (44;60) 44 (36;52) 68 (60;76) 50 (42;58)
56-65 184 42 (36;48) 33 (26;40) 57 (50;64) 36 (28;44)
66-77 102 60 (50;70) 44 (35;55) 66 (58;74) 45 (33;57)
p.=0.02 p.=0.06
Breast tumour location:
lateral quadrants 66 67 (56;78) 48 (38;58) 78 (68;88) 50 (40;60)
central and medial quadrants 441 45 (41;49) 36 (32;40) 60 (56;64) 41 (36;46)
p.=0.012 p.=0.02
T1+T2 381 51 (46;56) 40 (35;45) 67 (62;72) 45 (39;51)
T3+T4 126 38 (30;46) 28 (20;36) 48 (39;57) 31 (23;39)
p.=0.001 p.=0.001
I° 8 87 87 100 90
IIA 80 67 (57;77) 59 (47;71) 78 (69;87) 62 (50;74)
IIB 301 49 (43;55) 42 (36;48) 62 (58;66) 43 (37;49)
IIIA 80 43 (32;54) 33 (23;43) 50 (40;60) 34 (24;44)
IIIB 38 29 (15;43) 20 (4;36) 36 (22;50) 21 (9;33)
p.=0.01 p.=0.01
Carcinoma type:
ductal invasive 332 46 (41;51) 37 (31;43) 63 (58;68) 40 (35;45)
lobular invasive 81 55 (44;66) 40 (28;52) 70 (60;80) 56 (44;68)
good prognostic group 27 70 (54;86) 50 (36;66) 79 (63;95) 60 (42;78)
no data 67 34 (23;45) 26 (15;37) 43 (31;55) 26 (15;37)
p.=0.005 p.=0.005
Extranodal extension:
No 127 65 (58;72) 54 (44;64) 76 (68;84) 59 (49;69)
Yes 380 42 (37;47) 32 (27;37) 58 (53;63) 36 (30;42)
p.=0.001 p.=001
Tumour Grade:
G I + G II 214 44 (37;51) 33 (26;40) 63 (57;69) 38 (31;45)
G III 82 44 (33;55) 32 (21;43) 51 (40;62) 32 (21;43)
no data 211 53 (46;60) 43 (36;50) 66 (60;72) 50 (43;57)
p.=0.17 p.=0.01
Vascular invasion:
No 370 50 (54;46) 40 (44;36) 65 (61;69) 46 (42;50)
Yes 137 40 (44;36) 27 (19;35) 54 (46;62) 31 (22;40)
p.=0.016 p.=0.049
Nodal Index^
<40% 215 63 (57;69) 51 (44;58) 74 (68;80) 57 (49;65)
40-60% 72 39 (28;50) 32 (20;44) 63 (57;69) 38 (26;50)
>60% 174 34 (27;31) 21 (14;28) 48 (40;56) 24 (16;32)
p.=0.001 p.=0.001
* 95% confidence limit
^Nodal Index: total number of axillary nodes involved divided by the number of axillary nodes excised
death risk than patients with lateral tumour location.
Extracapsular nodal infiltration increases the patients’
death risk by 70%, as compared to patients without
capsular infiltration. Patients with a nodal index below
40% are at a 1.5 or twofold lesser risk of death than
patients with the nodal index of between 40%-60% and
over 60% respectively. All other prognostic factors, such
as the patients’ hormonal status, concomitant diseases,
duration of case history, the breast laterality, the size of
the primary tumour, the histopathological type and grade
of the tumour were found to be statistically non-
significant in the multivariate analysis.
10-year DFS in the entire group irradiated according
to technique A and B was 40% (34;46), 32% (26, 38),
respectively, with a 95% confidence interval – Figure 1.
A n a l y s i s  o f  f a i l u r e s
During the first 5 years of observation a recurrence of
the malignancy was observed in 226 patients (46%) – in
197 of these (40%) we observed distant failures, in 29
(6%) – isolated loco-regional recurrence. It was proved
that distant metastases are the main cause of failure
(197/226 – 87%) as compared to only 13% within the
loco-regional area. In 18 cases (62%) the recurrence was
limited to the thoracic wall, in 6 (21%) – it was found in
the regional lymph nodes and in the remaining 5 (17%) it
was located both in the lymph nodes and in the thoracic
wall.
During the entire period of observation (median of
10 yrs.) loco-regional recurrence (isolated or simultaneous
with distant failures) was found in 71/507 patients (14%).
54 cases (74%) of recurrences were observed during the
first 5 years, and 90% – during 6.5 years – Figure 2. We
found no difference as to the frequency of loco-regional
failure between patients from group A and group B
(44/313 – 14% – vs. 27/194 – 14%) – see Table V.
In both groups the most common site of recurrence
was the chest wall – 10% and 9.3%, respectively.
Recurrences within the different nodal sites were
observed sporadically (0.3-1.7% of patients) – see Table V.
We enhanced the analysis of loco-regional failures
within the chest wall by determining the influence of the
T stage and pN (as measured by the nodal index) and
their relation to the applied irradiation technique. We
found that in the case of patients with T1-T2 tumours
and nodal metastases these failures occurred in 11% of
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Table III. Cox’s model factors and the risk of recurrence of breast
cancer or death
Variable Relative risk P – value
Age [29, 45]– ref. 0.007
[45, 55] 0.638 0.015
[55, 65] 0.813 0.225
[65, 77] 0.528 0.002
Lateral – ref. vs
central or medial quadrants 1.472 0.005
No extranodal extension – ref. vs
extranodal extension 1.585 0.011
Nodal Index
<40 – ref. <0.0001
40-60 1.767 0.002
>60 2.262 <0.0001
Table IV. Cox’s model factors and the risk of death due to breast
cancer
Variable Relative risk P – value
Lateral – ref. vs
central or medial quadrants 1.382 0.041
No extranodal extension – ref. vs
extranodal extension 1.740 0.049
Nodal Index
<40 – ref. <0.0001
40-60 1.481 0.0457
>60 2.197 <0.0001
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Figure 1. Disease free survival in respect to the radiotherapy technique
in postmastectomy breast cancer patients
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Figure 2. Cumulative loco-regional recurrence in 71/507- 14%,
postmastectomy breast cancer patients
patients from group A and 8% of patients from group
B. Patients with T3-T4 tumours had an identical (15%)
ratio of chest wall recurrence, regardless of the irradiation
technique- Table VI.
We also observed that the recurrence risk grew with
the increase of the nodal index, although more rapidly
in group B. Even with a low nodal index (below 40%)
chest wall recurrence occurred in 8.5% of patients from
group A – Table VII.
Tr e a t m e n t  t o l e r a n c e  a n d  e a r l y  a n d  l a t e
c o m p l i c a t i o n s
Among the 507 patients undergoing postoperative
irradiation 22 (4.3%) women failed to complete treatment
– 15 developed distant failures, 3 had stroke and 4
presented with exacerbation of previously observed heart
disease.
In 218/507 patients (43%) the total treatment time
was lengthened to more than 6 weeks. The main cause of
elongation was the long waiting list for the electron beam
irradiation of the chest wall or of the internal mammary
lymph nodes. Treatment delays were also caused by
apparatus failures and conservation jobs.
Among the 485 patients who had completed
treatment 40 (8.2%) reported complications which
necessitated treatment delays. The most common cause
for these delays was leucopoenia (leukocyte count below
2500/mm3), which occurred in 27/485 patients (5.6%),
who were all concurrently receiving CMF chemotherapy.
Early skin reactions after Co60 treatment were
moderate (grade 1 and 2 in the RTOG-EORTC scale).
However, 17% of patients irradiated with the electron
beam to the chest wall and 3% irradiated with the same
technique to the internal mammary nodes developed
severe skin reactions in the form of moist desquamation
(grade 3).
An analysis of late complications was carried out in
269 patients, who had survived at least 5 years without
disease recurrence. Late skin reactions within the Co60
treated areas were all grade 1. Minor teleangiectasiae
(grade 2) were observed on the chest wall and in the
sternal region in 73% of patients. Grade 3 late skin
reactions on the chest wall were observed only in 3% of
patients. In 27 patients (10%) we observed lymphoedema
of the upper extremity. In 10 cases (3.7%) the diameter of
the unilateral upper arm was 4 cm greater than the
diameter of the contralateral arm.
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Table V. Rate and localization of loco-regional failures (LRF) in relation to the radiotherapy technique
LRF in regions (%)
RT Technique N CW CW+PN Sup/inf.clavicular Axilla Parasternal Total
“A”
PN alone 313 33 (10) 4 (1.5) 2 (0.7) 4 (1.5) 1 (0,3) 44 (14)
„B”
PN + CW 194 18 (9.3) 2 (1) 3 (1.7) 2 (1) 2 (1) 27 (14)
Total 507 51 (10) 6 (1.2) 5 (1) 6 (1.2) 3 (0.6) 71 (14)
N -Number of pts.; RT – radiotherapy; PN – Peripheral nodes; CW – chest wall; Sup/inf.clavicular – supra and/or infra clavicular region
Table VI. Chest wall recurrence in relation to the radiotherapy technique and T-stage in 458 patients with pN1
Radiotherapy Technique
“A” “B”
T-stage N Chest wall recurrence (%) N Chest wall recurrence (%)
T1 + T2 244 27 (11) 96 8 (8)
T3 + T4 39 6 (15) 79 12 (15)
Total 283 33 (12) 175 20 (11)
Table VII. Chest wall recurrence in relation to radiotherapy technique and nodal index in 461 patients with a stated number of nodes
Radiotherapy Technique
“A” “B”
Nodal Index N Chest wall recurrence (%) N Chest wall recurrence (%)
< 40 141 12 (8.5) 74 3 (4)
40 – 60 45 4 (9) 27 2 (7)
>60 98 13 (13) 76 10 (13)
Total 284 29 (10) 177 15 (8.5)
In 40/269 patients (15%) we observed late com-
plications arising from adjuvant treatment after mastec-
tomy. The most common disorders included haemato-
logical problems observed in 12% of patients (grade 2-3
according to NCI CTC) which lasted from 6 to 12 months.
In 8.5% of patients we observed recurrent infections
which deteriorated the quality of life (erysipelas, herpes
zoster, abscesses). Post-irradiative pulmonary fibrosis
with no clinical symptoms was observed in 6 patients
(2.2%). Transient brachial plexopathy was observed in 1
patient (0.4%) and exacerbation of coronary heart disease
necessitating treatment was observed in 4 patients (1.5%),
all irradiated on the left side of the chest. We observed no
exacerbation of coronary heart disease in patients
irradiated to the right side of the chest. Post-irradiative
hypothyrosis was observed in 1 case (0.4%).
Discussion
At present it is believed that chest wall irradiation after
mastectomy is a necessity, because most loco-regional
recurrences are found in this area, and therefore such
treatment affects not only local success but also increases
patient survival. However, there are no conclusive litera-
ture reports concerning regional lymph node irradiation,
mostly arising from the risk of morbidity [16].
In view of our own experiences and the reports of
other authors [17] our policy concerning postoperative
radiotherapy has been altered in 1995. All patients who
qualify for radiotherapy after mastectomy are treated
with the “peripheral + chest wall” technique (i.e. B).
Such an approach has been rendered possible by the
availability of modern methods of radiotherapy planning
with the use of 3D and treatment with the electron beam.
The “peripheral” technique, which was widely used in
the years 1985-1994, was introduced due to the
anticipation of treatment toxicity during time of the
widespread enthusiasm for adjuvant chemotherapy. At
that time Bonadonna reported his results, according to
which he achieved an improvement in the survival of
postmenopausal breast cancer patients after adjuvant
chemotherapy according to the CMF programme and
without radiotherapy [18]. Stjernsward in 1974 [19] and
Cusick in 1987 [20] reported an increased risk of death in
irradiated patients. In view of their findings the general
opinion turned in favour of chemotherapy, while pos-
toperative radiotherapy became less common. This
caused postoperative radiotherapy to be limited and
practically administered only in postmenopausal women,
as in this group of patients the CMF programme proved
less effective [18]. In a further analysis Rudqvist [21] and
Cuzick [22] reported that the main cause of the increased
death ratio after radiotherapy is connected to cardio-
vascular complications in fact associated with old-
fashioned techniques and exceeding doses applied to the
coronary vessels. This was later confirmed in large
epidemiological population studies. It was proven that
irradiation of patients with cancer of the left breast was
associated with a 20% higher death risk due to cardio-
vascular causes, as compared to patients irradiated for
cancer of the right breast [23]. Because of these literature
reports at the Institute of Oncology in Warsaw we had
also decided to limit the use of postoperative radiotherapy
among premenopausal patient, and we introduced the
“peripheral” technique (A) in which (in order to limit
potential cardiotoxicity) only the regional lymph nodes
were irradiated. Qualification was arbitrary; however
there was a tendency to apply technique A in less
advanced cases and technique B (which included the
regional lymph nodes and the chest wall) in more
advanced cases. In the entire studied group 10-year DFS
for patients irradiated according to the A and B method
was 40% and 32%, respectively, which is probably
associated with the fact that patients referred for
technique B had more advanced disease.
Our analysis has confirmed the commonly known
fact that the main cause of failure in breast cancer is
associated with distant metastases. Among the 46% of
failures observed in the first 5 years distant metastases
were responsible for 40% of failures, and loco-regional
recurrence only 6%. This can result from too less
aggressive adjuvant systemic treatment. At present
a majority of the analysed patients would have been
receiving treatment, probably with the use of anthra-
cyclines or taxoids. Tamoxifene was administered only to
30% of patients, and in the majority of cases the estrogen
and progesterone receptors were not investigated. It is
common knowledge that the presence of these receptors
is a predictive factor in the treatment of breast cancer
and their concentration is a condition for hormono-
therapy [23, 24].
In Poland breast cancer is responsible for the highest
ratio of cancer-induced mortality in women [1] and in
the course of population studies it is still reported that the
results of breast cancer treatment in Poland are worse
the average European results [25]. Our material is
representative for the time period, during which it had
been observed. 5- and 10-year prognosed DFS and OS for
patients consecutively irradiated between the years 1985
and 1994 was 48%, 38% and 62%, 42%, respectively.
However, the results of treatment depend upon numerous
prognostic factors, especially advancement of the disease,
and therefore the comparison of these results is very
difficult (Table II).
An analysis of failures has shown that recurrences
within the chest wall are more common (2.8 times more
likely) than nodal recurrences – Table V. We believe that
in the case of patients with nodal metastases the chest
wall should be irradiated even in the case of smaller
tumours – pT1-pT2, and the same can be said for patients
with a low nodal index. To support this it is worth stressing
that in group A recurrences were observed in 11% and
8.5% of cases, respectively – Table VI and VII.
In 1995 we abandoned the A technique. Patients
referred for postoperative radiotherapy are irradiated to
the chest wall with an electron beam. It is well known
that the frequency of recurrences within the chest wall
increases with an increase in the size of the primary
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tumour and with the increase of the advancement of the
disease within the axillary fossa [26, 27]. We have also
observed such correlations. In patients with T3-T4
tumours or with a nodal index of over 60% we observed
15% and 13% of chest wall recurrences, respectively –
Table VI and VII. In this group of patients an increase of
the radiation dose should be considered. There probably
exists a group of postmastectomy patients with axillary
lymph node metastases who are not in need of
postoperative irradiation. The problem lies in patient
stratification and in the individual selection of such
persons – and, as an issue, requires further research [26,
28-31].
The analysis of the time of the occurrence of loco-
regional failures (both isolated and simultaneous with
distant recurrence) has shown, that 76% of these
appeared in the first 5 years of observation, and as many
as 90% in the first 6.5 years of observation. Literature
data report 70% of failures during the first 3 years and 80-
90% of failures during the first 5 years [24, 27, 32].
Recht et al. [24] have published an analysis of 10-
year loco-regional failure rate in a group of 2016 patients
participating in four randomised studies performed by
the Eastern Cooperative Oncology Group. After mastec-
tomy due to breast cancer the patients received adjuvant
chemo- and/or hormonotherapy without radiotherapy.
The authors observed 13% of isolated loco-regional
failures, while the 10-year cumulated risk of isolated and
simultaneous failures was estimated to be 28.7% in
patients with more than 3 lymph nodes involved. In our
material similar percentages were much lower – 6% and
14% respectively, and we associate this with radiation
therapy. However, our analysis is retrospective and
therefore all comparisons with the cited data are
superficial and cannot form the base for conclusions.
An evaluation of 5-year and 10-year DFS and OS
probability has confirmed the influence of classical
prognostic factors associated with the advancement of
the disease. In a univariate analysis we did not confirm the
worse prognosis of patients with cancer of the left breast
as compared with patients with cancer of the right breast.
Patients with central and medial location of the tumour
have poorer prognosis than patients with lateral location.
These observations have also been reported by other
authors [33, 34]. Maybe this arises from the higher
probability of dissemination via the internal mammary
lymph nodes to the mediastinum and further, and maybe
the phenomenon is associated with cardiotoxicity.
However, we did not observe increased cardiotoxicity or
an increased risk of death due to cardiac reasons. Only in
4 patients (1.5%) did we observe exacerbation of coronary
heart disease which demanded treatment and which was
associated with prior irradiation to the left side of the
chest. However in 25 patients (5%) we were unable to
determine the cause of death.
In a multivariate analysis we had found that younger
patients (below 45 years of age) with a medial primary
tumour location and numerous nodal metastases
with extracapsular extension have the highest risk of
recurrence and/or death due to breast cancer. The nodal
index was found to be the most important prognostic
factor. Patients in whom the nodal factor is higher than
60% have 2.3 times higher risk of recurrence and
a twofold higher risk of death than patients in whom the
nodal index was below 40%.
When we compare the present results with the
results obtained in the course of breast cancer treatment
at the Institute of Oncology in Warsaw and in Cracow in
the eighties we cannot fail to notice that despite the time
lapse the results have remained unchanged in the
different prognostic subgroups [35, 36]. Patients below
the age of 46, with a central location of the tumour
originally over 5 cm in diameter and with numerous (>3)
involved nodes with extracapsular extension have poor
prognosis. Korzeniowski [35] stresses the influence of the
histopathologic grade not only as a risk factor of distant
failures, but also as a risk factor of loco-regional
recurrence. In the multivariate analysis performed in our
material the histopathological grade did not statistically
significantly influence prognosis. Maybe this arises from
the fact that the number of patients in whom the
histopathologic grade was microscopically determined
was rather low.
Complications necessitating treatment delay were
observed in 40/485 patients (8.2%). The main cause of
such delays was leucopoenia in patients receiving con-
comitant chemotherapy. No optimal methods of com-
bining radio- and chemotherapy in postmastectomy
patients have been reported. Basing upon our experiences
at present we begin radiotherapy 4 weeks after the
completion of chemotherapy in order to achieve better
treatment tolerance.
Excessive skin reactions and pharyngeal reactions
were seldom the cause for treatment delay – 2.6% and
1.4% of patients, respectively. A majority of early skin
reactions observed in the studied group were noted as
stage 1 and 2. Nevertheless, in view of the individual
observation of patients we have decreased the total dose
from 46 Gy calculated in the 80% isodose in 23 fractions
to 45 Gy calculated in the 90% isodose in 20 fractions. We
have also changed the PTV isodose from 80% to 85%.
Every patient treated at the Institute of Oncology
undergoes individual and group rehabilitation. Maybe
this is the reason why lymphoedema of the unilateral
upper extremity is observed only in 10% of patients.
We observed no clinically significant post-irradiation
pulmonary fibrosis. The relatively low ratio of cardio-
toxicity (1.5%) may be proof of correct treatment
planning, which includes shielding the heart. Nonetheless,
late cardiovascular complications should be assessed over
an observation period longer than 10 years [10]. Transient
symptoms of post-irradiation brachial plexopathy were
observed only in one patient (0.4%). We observed no
permanent plexopathy. This suggests that we apply
a correct technique of supraclavicular and axillary lymph
node irradiation. These sites were irradiated using the
isocentric technique, without changing the position of
the patient. Patient repositioning during radiotherapy is
227
the main cause of complications, as the fields overlap
and the dose applied to the brachial plexus exceeds its
tolerance.
In the last five years there has been an increase in
the interest concerning the postmastectomy irradiation.
Danish and Canadian studies have shown that adjuvant
radiotherapy not only provides better loco-regional
control but also improves the 10- and 15-year survival
rate, as compared to patients receiving only adjuvant
chemotherapy [6-8]. The introduction of modern methods
of 3D treatment planning to limit the risk of late
complications – especially pulmonary and cardiac [28,
37, 38]. Nevertheless, these issues demand careful and
scrutinizing research because, at present, all patients with
nodal metastases receive systemic treatment. Despite the
fact, that communications concerning an improvement
of patient survival after postoperative radiotherapy have
not yet been confirmed by many scientists, especially the
Americans, nobody questions the necessity to administer
adjuvant radiotherapy to postmastectomy breast cancer
patients who report with a number of poor prognostic
factors, especially with the use of modern treatment
methods.
Summary
1. 5- and 10-year prognosed DFS and OS for patients
consecutively irradiated between the years 1985 and
1994 was 48%, 38% and 62%, 42%, respectively.
2. The significant ratio of distant failures among the total
number of failures (87% during the first 5 years)
confirms the necessity of more effective systemic
therapy.
3. The most important prognostic factor influencing the
risk of recurrence and of death is the nodal index (the
ratio of involved lymph nodes among all dissected). If
it exceeds 60% the risk of recurrence and/or death
due to breast cancer is 2.2 times higher than in patients
with a nodal index of 40%.
4. The relatively low percentage of isolated loco-regional
recurrences (6% in 5 years) confirms the efficacy of
radiotherapy in the analysed group. Loco-regional
failures (both isolated and simultaneous with distant
recurrences) were observed in 14% of patients – 76%
of these failures appeared in the first 5 years of
observation, and as many as 90% in the first 6.5 years
of observation. Both in the case of technique A and B
the most often recurrence was observed within the
chest wall – 10% and 9.3% of patients, respectively.
Nodal recurrences were observed sporadically – in 0.3-
1.7% of patients.
5. The significantly more common local failures (in the
entire observation period – median of 10 yrs.) confirm
the need for irradiation of the chest wall in
postmastectomy patients with a T1-T2 primary tumour
(11% of recurrences) and axillary node involvement
(even with a nodal index below 40% – 8.5% of
recurrences). In 1995 the A technique has been
abandoned at the Institute of Oncology in Warsaw,
and the irradiated fields include the chest wall and the
regional lymph nodes.
6. The relatively low ratio of late complications (1.5%
cardiotoxicity and 10% lymphoedema of upper
extremity) allows to pronounce the technique used in
the Institute of Oncology as safe. It must, however, be
kept in mind that in order to provide a reliable analysis
of cardiotoxicity the observation period should be
longer than 10 years.
Jacek Ga∏ecki MD, PhD
Department of Teleradiotherapy
The Maria Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology
Roentgena 5 Str., 02-781 Warsaw
Poland
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